Heart scan tracer may reveal Chemo's effect on amyloid buildup

NCT ID NCT03333551

Terminated Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This pilot study tests whether a special PET scan tracer called 18F florbetapir can detect changes in amyloid protein deposits in the heart of people with AL cardiac amyloidosis who are receiving chemotherapy. Four participants will have a PET/CT scan before starting chemotherapy and again after six months of treatment. The goal is to see if the tracer's uptake in the heart changes as chemotherapy reduces amyloid levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F florbetapir (Amyvid) cardiac PET/CT imaging
What this could lead to: If successful, this imaging method could help doctors monitor how well chemotherapy is reducing amyloid buildup in the heart.
What could go wrong: This is a very small pilot study with only 4 participants, so results may not apply broadly. The imaging agent is not yet proven to track treatment response reliably.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Amyloid Neuropathies, Familial amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC AMYLOIDOSIS

Contacts and locations

Show contact details

Locations

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.